Iatrogenic hyperhomocysteinemia in patients with metabolic syndrome: A systematic review and metaanalysis

Atherosclerosis

Volumn 214, Issue 1, 2011, Pages 11-19

  Ntaios, George ^a   Savopoulos, Christos ^a   Chatzopoulos, Stavros ^a   Mikhailidis, Dimitri ^b   Hatzitolios, Apostolos ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Fibrates; Homocysteine; Hydrochlorothiazide; Metabolic syndrome; Metformin

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; AMLODIPINE; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEZAFIBRATE; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CIPROFIBRATE; COLESTYRAMINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FENOFIBRATE; GEMFIBROZIL; HOMOCYSTEINE; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; METOPROLOL; NICOTINIC ACID; OMAPATRILAT; ORAL ANTIDIABETIC AGENT; RIMONABANT; SIBUTRAMINE; SULFONYLUREA DERIVATIVE; TETRAHYDROLIPSTATIN; UNINDEXED DRUG;

BLOOD LEVEL; CARDIOVASCULAR RISK; HUMAN; HYPERHOMOCYSTEINEMIA; HYPOLIPEMIA; IATROGENIC DISEASE; METABOLIC SYNDROME X; MORTALITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW;

ADMINISTRATION, ORAL; AGED; ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS AS TOPIC; FIBRIC ACIDS; HOMOCYSTEINE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERHOMOCYSTEINEMIA; HYPERLIPIDEMIAS; HYPOGLYCEMIA; IATROGENIC DISEASE; METABOLIC SYNDROME X; METFORMIN; MIDDLE AGED;

EID: 78650802113     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.08.045     Document Type: Review

References (119)

1. McCully K.S. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969 July, 56(1):111-128.
2. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002, 288(October 16):2015-2022.
3. Brouwer I.A., van D.M., Thomas C.M.G., Duran M., Hautvast J.G.A.J., Eskes T.K.A.B., Steegers-Theunissen R.P. Low-Dose folic acid supplementation decreases plasma homocysteine concentrations: a randomised trial. Indian Heart J 2000 November, 52(7 Suppl):S53-S58.
4. Woo K.S., Chook P., Lolin Y.I., Sanderson J.E., Metreweli C., Celermajer D.S. Folic acid improves arterial endothelial function in adults with hyperhomocystinemia. J Am Coll Cardiol 1999 December, 34(7):2002-2006.
5. Ntaios G., Savopoulos C., Karamitsos D., Economou I., Destanis E., Chryssogonidis I., Pidonia I., Zebekakis P., Polatides C., Sion M., Grekas D., Hatzitolios A. The effect of folic acid supplementation on carotid intima-media thickness in patients with cardiovascular risk: A randomized, placebo-controlled trial. Int J Cardiol 2010, 143:16-19.
6. Constans J., Blann A.D., Resplandy F., Parrot F., Renard M., Seigneur M., Guerin V., Boisseau M., Conri C. Three months supplementation of hyperhomocysteinaemic patients with folic acid and vitamin B6 improves biological markers of endothelial dysfunction. Br J Haematol 1999 December, 107(4):776-778.
7. Nappo F., De R.N., Marfella R., De L.D., Ingrosso D., Perna A.F., Farzati B., Giugliano D. Impairment of endothelial functions by acute hyperhomocysteinemia and reversal by antioxidant vitamins. JAMA 1999 June, 281(22):2113-2118.
8. Hodis H.N., Mack W.J., Dustin L., Mahrer P.R., Azen S.P., Detrano R., Selhub J., Alaupovic P., Liu C.R., Liu C.H., Hwang J., Wilcox A.G., Selzer R.H., High-dose B vitamin supplementation and progression of subclinical atherosclerosis: a randomized controlled trial. Stroke 2009 March, 40(3):730-736.
9. Toole J.F., Malinow M.R., Chambless L.E., Spence J.D., Pettigrew L.C., Howard V.J., Sides E.G., Wang C.H., Stampfer M. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004 February, 291(5):565-575.
10. Bonaa K.H., Njolstad I., Ueland P.M., Schirmer H., Tverdal A., Steigen T., Wang H., Nordrehaug J.E., Arnesen E., Rasmussen K. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006 April, 354(15):1578-1588.
11. Lonn E., Yusuf S., Dzavik V., Doris C., Yi Q., Smith S., Moore-Cox A., Bosch J., Riley W., Teo K. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 2001 February, 103(7):919-925.
12. Jamison R.L., Hartigan P., Kaufman J.S., Goldfarb D.S., Warren S.R., Guarino P.D., Gaziano J.M. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA 2007 September, 298(10):1163-1170.
13. Ebbing M., Bleie O., Ueland P.M., Nordrehaug J.E., Nilsen D.W., Vollset S.E., Refsum H., Pedersen E.K., Nygard O. Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial. JAMA 2008 August, 300(7):795-804.
14. Albert C.M., Cook N.R., Gaziano J.M., Zaharris E., MacFadyen J., Danielson E., Buring J.E., Manson J.E. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. JAMA 2008 May, 299(17):2027-2036.
15. Ntaios G., Savopoulos C., Hatzitolios A. Lowering homocysteine with B vitamins in patients with coronary artery disease. JAMA 2008 December, 300(24):2852-2853.
16. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., Gordon D.J., Krauss R.M., Savage P.J., Smith S.C., Spertus J.A., Costa F. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart Lung, and Blood Institute Scientific Statement. Circulation 2005 October, 112(17):2735-2752.
17. Gami A.S., Witt B.J., Howard D.E., Erwin P.J., Gami L.A., Somers V.K., Montori V.M. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007 January, 49(4):403-414.
18. Atar I., Korkmaz M.E., Demircan S., Atar I.A., Bozbas H., Aydinalp A., Ozin B., Yildirir A., Muderrisoglu H. Beta blocker effects on plasma homocysteine levels in patients with hypertension. Atherosclerosis 2005 August, 181(2):399-402.
19. Campbell D.J., Woodward M., Chalmers J.P., Colman S.A., Jenkins A.J., Kemp B.E., Neal B.C., Patel A., MacMahon S.W. Perindopril-based blood pressure-lowering therapy reduces amino-terminal-pro-B-type natriuretic peptide in individuals with cerebrovascular disease. J Hypertens 2007 March, 25(3):699-705.
20. Demir M., Ozaydin M., Varol E., Dogan A., Altinbas A. Effects of metoprolol and diltiazem on plasma homocysteine levels in patients with isolated coronary artery ectasia. Anadolu Kardiyol Derg 2009 February, 9(1):69-70.
21. Derosa G., Cicero A.F., Ciccarelli L., Fogari R. A randomized, double-blind, controlled, parallel-group comparison of perindopril and candesartan in hypertensive patients with type 2 diabetes mellitus. Clin Ther 2003 July, 25(7):2006-2021.
22. Korkmaz M.E., Atar I., Tayfun E., Yildirir A., Ulucam M., Ozin B., Muderrisoglu H., Turan M. Effects of a beta-blocker and spironolactone on plasma homocysteine levels. Int J Cardiol 2003 March, 88(1):119-120.
23. Muda P., Kampus P., Zilmer M., Ristimae T., Fischer K., Zilmer K., Kairane C., Teesalu R. Effect of antihypertensive treatment with candesartan or amlodipine on glutathione and its redox status, homocysteine and vitamin concentrations in patients with essential hypertension. J Hypertens 2005 January, 23(1):105-112.
24. Neal B., MacMahon S., Ohkubo T., Brnabic A., Tonkin A. Effects of the vasopeptidase inhibitor, omapatrilat, in 723 patients with coronary heart disease. J Renin Angiotensin Aldosterone Syst 2002 December, 3(4):270-276.
25. Poduri A., Kaur J., Thakur J.S., Kumari S., Jain S., Khullar M. Effect of ACE inhibitors and beta-blockers on homocysteine levels in essential hypertension. J Hum Hypertens 2008 April, 22(4):289-294.
26. Rizos E., Bairaktari E., Kostoula A., Hasiotis G., Achimastos A., Ganotakis E., Elisaf M., Mikhailidis D.P. The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that of atenolol plus pravastatin in hypertensive patients with dyslipidemia: a pilot study. J Cardiovasc Pharmacol Ther 2003 June, 8(2):127-134.
27. Sebekova K., Gazdikova K., Syrova D., Blazicek P., Schinzel R., Heidland A., Spustova V., Dzurik R. Effects of ramipril in nondiabetic nephropathy: improved parameters of oxidatives stress and potential modulation of advanced glycation end products. J Hum Hypertens 2003 April, 17(4):265-270.
28. Westphal S., Rading A., Luley C., Dierkes J. Antihypertensive treatment and homocysteine concentrations. Metabolism 2003 March, 52(3):261-263.
29. Ansquer J.C., Foucher C., Rattier S., Taskinen M.R., Steiner G. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis 2005 March, 45(3):485-493.
30. Bissonnette R., Treacy E., Rozen R., Boucher B., Cohn J.S., Genest J. Fenofibrate raises plasma homocysteine levels in the fasted and fed states. Atherosclerosis 2001 April, 155(2):455-462.
31. de Lorgeril M., Salen P., Paillard F., Lacan P., Richard G. Lipid-lowering drugs and homocysteine. Lancet 1999 January, 353(9148):209-210.
32. Dierkes J., Westphal S., Luley C. Serum homocysteine increases after therapy with fenofibrate or bezafibrate. Lancet 1999 July, 354(9174):219-220.
33. Dierkes J., Westphal S., Kunstmann S., Banditt P., Lossner A., Luley C. Vitamin supplementation can markedly reduce the homocysteine elevation induced by fenofibrate. Atherosclerosis 2001 September, 158(1):161-164.
34. Genest J., Frohlich J., Steiner G. Effect of fenofibrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in type 2 diabetes mellitus. Am J Cardiol 2004 April, 93(7):848-853.
35. Giral P., Bruckert E., Jacob N., Chapman M.J., Foglietti M.J., Turpin G. Homocysteine and lipid lowering agents. A comparison between atorvastatin and fenofibrate in patients with mixed hyperlipidemia. Atherosclerosis 2001 February, 154(2):421-427.
36. Harats D., Yodfat O., Doolman R., Gavendo S., Marko D., Shaish A., Sela B.A. Homocysteine elevation with fibrates: is it a class effect?. Isr Med Assoc J 2001 April, 3(4):243-246.
37. Hiukka A., Leinonen E., Jauhiainen M., Sundvall J., Ehnholm C., Keech A.C., Taskinen M.R. Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus. Diabetologia 2007 October, 50(10):2067-2075.
38. Landray M.J., Townend J.N., Martin S., Martin U., Wheeler D.C. Lipid-lowering drugs and homocysteine. Lancet 1999 June 5, 353(9168):1974-1975.
39. MacCallum P.K., Cooper J.A., Rumley A., Lowe G.D., Meade T.W. Effect of bezafibrate on plasma homocysteine concentration in men with lower extremity arterial disease. J Thromb Haemost 2004 February, 2(2):364-365.
40. Malik J., Melenovsky V., Wichterle D., Haas T., Simek J., Ceska R., Hradec J. Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial--FAT). Cardiovasc Res 2001 November, 52(2):290-298.
41. Mayer O., Simon J., Holubec L., Pikner R., Trefil L. Folate co-administration improves the effectiveness of fenofibrate to decrease the lipoprotein oxidation and endothelial dysfunction surrogates. Physiol Res 2006, 55(5):475-481.
42. Mayer O., Simon J., Holubec L., Pikner R., Subrt I. Fenofibrate-induced hyperhomocysteinemia may be prevented by folate co-administration. Eur J Clin Pharmacol 2003 September, 59(5-6):367-371.
43. Melenovsky V., Malik J., Wichterle D., Simek J., Pisarikova A., Skrha J., Poledne R., Stavek P., Ceska R. Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia. Am Heart J 2002 October, 144(4):E6.
44. Melenovsky V., Stulc T., Kozich V., Grauova B., Krijt J., Wichterle D., Haas T., Malik J., Hradec J., Ceska R. Effect of folic acid on fenofibrate-induced elevation of homocysteine and cysteine. Am Heart J 2003 July, 146(1):110.
45. Stulc T., Melenovsky V., Grauova B., Kozich V., Ceska R. Folate supplementation prevents plasma homocysteine increase after fenofibrate therapy. Nutrition 2001 September, 17(9):721-723.
46. Milionis H.J., Papakostas J., Kakafika A., Chasiotis G., Seferiadis K., Elisaf M.S. Comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia. J Clin Pharmacol 2003 August, 43(8):825-830.
47. Playford D.A., Watts G.F., Croft K.D., Burke V. Combined effect of coenzyme Q10 and fenofibrate on forearm microcirculatory function in type 2 diabetes. Atherosclerosis 2003 May, 168(1):169-179.
48. Potaczek D.P., Undas A., Celinska-Lowenhoff M., Szczeklik A. The I allele of the angiotensin-converting enzyme gene polymorphism may determine an increase in homocysteine levels in fibrate-treated subjects. Cardiovasc Drugs Ther 2006 June, 20(3):229-232.
49. Sebestjen M., Keber I., Zegura B., Simcic S., Bozic M., Fressart M.M., Stegnar M. Statin and fibrate treatment of combined hyperlipidemia: the effects on some novel risk factors. Thromb Haemost 2004 November, 92(5):1129-1135.
50. Syvanne M., Whittall R.A., Turpeinen U., Nieminen M.S., Frick M.H., Kesaniemi Y.A., Pasternack A., Humphries S.E., Taskinen M.R. Serum homocysteine concentrations, gemfibrozil treatment, and progression of coronary atherosclerosis. Atherosclerosis 2004 February, 172(2):267-272.
51. Terra S.G., Francone O.L., Contant C.F., Gao X., Lewin A.J., Nguyen T.T. Efficacy and safety of a potent and selective peroxisome proliferator activated receptor alpha agonist in subjects with dyslipidemia and type 2 diabetes mellitus. Am J Cardiol 2008 August, 102(4):434-439.
52. Westphal S., Dierkes J., Luley C. Effects of fenofibrate and gemfibrozil on plasma homocysteine. Lancet 2001 July, 358(9275):39-40.
53. Jonkers I.J., de Man F.H., Onkenhout W., van der Laarse A., Smelt A.H. Implication of fibrate therapy for homocysteine. Lancet 1999 October, 354(9185):1208.
54. Keech A., Simes R.J., Barter P., Best J., Scott R., Taskinen M.R., Forder P., Pillai A., Davis T., Glasziou P., Drury P., Kesaniemi Y.A., Sullivan D., Hunt D., Colman P., d'Emden M., Whiting M., Ehnholm C., Laakso M. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005 November, 366(9500):1849-1861.
55. Jula A., Marniemi J., Huupponen R., Virtanen A., Rastas M., Ronnemaa T. Effects of diet and simvastatin on serum lipids, insulin, and antioxidants in hypercholesterolemic men: a randomized controlled trial. JAMA 2002 February, 287(5):598-605.
56. Bolaman Z., Kadikoylu G., Ozgel N., Yenisey C. Effects of atorvastatin on coagulation parameters and homocysteine in patients with primary hypercholesterolemia. J Natl Med Assoc 2006 August, 98(8):1273-1277.
57. Capecchi P.L., Lazzerini P.E., Maccherini M., Guideri F., Lisi G., Acampa M., Cuomo A., Diciolla F., Toscano M., Laghi P.F. Pravastatin treatment-associated reduction in plasma homocysteine in heart-transplanted patients. Transplant Proc 2002 June, 34(4):1273-1274.
58. Davis M., Atwal A.S., Nair D.R., Jagroop I.A., Seifalian A.M., Mikhailidis D.P., Hamilton G. The effect of short-term lipid lowering with atorvastatin on carotid artery intima media thickness in patients with peripheral vascular disease: a pilot study. Curr Med Res Opin 2000, 16(3):198-204.
59. Haak E., Abletshauser C., Weber S., Goedicke C., Martin N., Hermanns N., Lackner K., Kusterer K., Usadel K.H., Haak T. Fluvastatin therapy improves microcirculation in patients with hyperlipidaemia. Atherosclerosis 2001 April, 155(2):395-401.
60. Kaya C., Cengiz S.D., Berker B., Demirtas S., Cesur M., Erdogan G. Comparative effects of atorvastatin and simvastatin on the plasma total homocysteine levels in women with polycystic ovary syndrome: a prospective randomized study. Fertil Steril 2009 August, 92(2):635-642.
61. Lu T.M., Ding Y.A., Leu H.B., Yin W.H., Sheu W.H., Chu K.M. Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia. Am J Cardiol 2004 July, 94(2):157-161.
62. Luftjohann D., Sigit J.I., Locatelli S., von B.K., Schmidt H.H. High-dose simvastin (80mg/day) decreases plasma concentrations of total homocyst(e)ine in patients with hypercholesteromia. Atherosclerosis 2001 March, 155(1):265-266.
63. MacMahon M., Kirkpatrick C., Cummings C.E, Clayton A., Robinson P.J., Tomiak R.H., Liu M., Kush D., Tobert J. A pilot study with simvastatin and folic acid/vitamin B12 in preparation for the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH). Nutr Metab Cardiovasc Dis 2000 August, 10(4):195-203.
64. Malyszko J., Malyszko J.S., Brzosko S., Pawlak K., Mysliwiec M. Effects of fluvastatin on homocysteine and serum lipids in kidney allograft recipients. Ann Transplant 2002, 7(1):52-54.
65. Malyszko J., Malyszko J.S., Hryszko T., Mysliwiec M. Influence of simvastatin on aspects of thrombogenesis in CAPD pa*ti*ents. Perit Dial Int 2003 May, 23(3):260-266.
66. Milionis H.J., Gazi I.F., Filippatos T.D., Tzovaras V., Chasiotis G., Goudevenos J., Seferiadis K., Elisaf M.S. Starting with rosuvastatin in primary hyperlipidemia--Is there more than lipid lowering?. Angiology 2005 September, 56(5):585-592.
67. Miltiadous G., Papakostas J., Chasiotis G., Seferiadis K. Elisaf M. Statins and homocysteine. Atherosclerosis 2003 January, 166(1):199-200.
68. Nanayakkara P.W., van G.C., ter Wee P.M., Scheffer P.G., van Ittersum F.J., Twisk J.W., Teerlink T., van D.W., Stehouwer C.D. Effect of a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on carotid intima-media thickness, endothelial function, and renal function in patients with mild to moderate chronic kidney disease: results from the Anti-Oxidant Therapy in Chronic Renal Insufficiency (ATIC) Study. Arch Intern Med 2007 June, 167(12):1262-1270.
69. Navarro J.F., Mora C., Muros M., Garcia-Idoate G. Effects of atorvastatin on lipid profile and non-traditional cardiovascular risk factors in diabetic patients on hemodialysis. Nephron Clin Pract 2003, 95(4):c128-c135.
70. Nieminen T., Knuuti J., Hamelahti P., Kahonen M., Laaksonen R., Janatuinen T., Vesalainen R., Nuutila P., Jokela H., Lehtimaki T. Coronary reactivity, homocysteine and methylenetetrahydrofolate reductase gene variation in young men during pravastatin therapy. Vascul Pharmacol 2007 August, 47(2-3):113-117.
71. Pereira E.C., Bertolami M.C., Faludi A.A., Sevanian A., Abdalla D.S. Antioxidant effect of simvastatin is not enhanced by its association with alpha-tocopherol in hypercholesterolemic patients. Free Radic Biol Med 2004 November, 37(9):1440-1448.
72. Ridker P.M., Shih J., Cook T.J., Clearfield M., Downs J.R., Pradhan A.D., Weis S.E., Gotto A.M. Plasma homocysteine concentration, statin therapy, and the risk of first acute coronary events. Circulation 2002 April, 105(15):1776-1779.
73. Santini E., Madec S., Corretti V., Ferrannini E., Solini A. Effect of statins on soluble CD40 ligand in hypercholesterolemic Type 2 diabetic patients. J Endocrinol Invest 2008 July, 31(7):660-665.
74. Sasaki S., Kuwahara N., Kunitomo K., Harada S., Yamada T., Azuma A., Takeda K., Nakagawa M. Effects of atorvastatin on oxidized low-density lipoprotein, low-density lipoprotein subfraction distribution, and remnant lipoprotein in patients with mixed hyperlipoproteinemia. Am J Cardiol 2002 February, 89(4):386-389.
75. Sbarouni E., Kyriakides Z.S., Kremastinos D.T. The effect of hormone replacement therapy and simvastatin on plasma homocysteine. J Womens Health (Larchmt) 2005 March, 14(2):154-158.
76. Scharnagl H., Vogel M., Abletshauser C., Freisinger F., Stojakovic T., Marz W. Efficacy and safety of fluvastatin-extended release in hypercholesterolemic patients: morning administration is equivalent to evening administration. Cardiology 2006, 106(4):241-248.
77. Vigna G.B., Donega P., Zanca R., Barban A., Passaro A., Pansini F., Bonaccorsi G., Mollica G., Fellin R. Simvastatin, transdermal patch, and oral estrogen-progestogen preparation in early-postmenopausal hypercholesterolemic women: a randomized, placebo-controlled clinical trial. Metabolism 2002 November, 51(11):1463-1470.
78. Brown B.G., Zhao X.Q., Chait A., Fisher L.D., Cheung M.C., Morse J.S., Dowdy A.A., Marino E.K., Bolson E.L., Alaupovic P., Frohlich J., Albers J.J., Simvastatin, niacin antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001 November, 345(22):1583-1592.
79. Garg R., Malinow M., Pettinger M., Upson B., Hunninghake D. Niacin treatment increases plasma homocyst(e)ine levels. Am Heart J 1999 December, 138(6 Pt 1):1082-1087.
80. Wang W., Basinger A., Neese R.A., Shane B., Myong S.A., Christiansen M., Hellerstein M.K. Effect of nicotinic acid administration on hepatic very low density lipoprotein-triglyceride production. Am J Physiol Endocrinol Metab 2001 March, 280(3):E540-E547.
81. Tonstad S., Knudtzon J., Sivertsen M., Refsum H., Ose L. Efficacy and safety of cholestyramine therapy in peripubertal and prepubertal children with familial hypercholesterolemia. J Pediatr 1996 July, 129(1):42-49.
82. Derosa G., D'Angelo A., Ragonesi P.D., Ciccarelli L., Piccinni M.N., Pricolo F., Salvadeo S.A., Montagna L., Gravina A., Ferrari I., Paniga S., Cicero A.F. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome. J Clin Pharm Ther 2006 August, 31(4):375-383.
83. Derosa G., Gaddi A.V., Ciccarelli L., Fogari E., Ghelfi M., Ferrari I., Cicero A.F. Long-term effect of glimepiride and rosiglitazone on non-conventional cardiovascular risk factors in metformin-treated patients affected by metabolic syndrome: a randomized, double-blind clinical trial. J Int Med Res 2005 May, 33(3):284-294.
84. Carlsen S.M., Folling I., Grill V., Bjerve K.S., Schneede J., Refsum H. Metformin increases total serum homocysteine levels in non-diabetic male patients with coronary heart disease. Scand J Clin Lab Invest 1997 October, 57(6):521-527.
85. Carlsen S.M., Kjotrod S., Vanky E., Romundstad P. Homocysteine levels are unaffected by metformin treatment in both nonpregnant and pregnant women with polycystic ovary syndrome. Acta Obstet Gynecol Scand 2007, 86(2):145-150.
86. Derosa G., Mugellini A., Ciccarelli L., Crescenzi G., Fogari R. Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin. Diabetes Res Clin Pract 2003 June, 60(3):161-169.
87. Derosa G., Franzetti I., Gadaleta G., Ciccarelli L., Fogari R. Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: comparison between glimepiride and metformin. Diabetes Nutr Metab 2004 June, 17(3):143-150.
88. Derosa G., D'Angelo A., Fogari E., Salvadeo S., Gravina A., Ferrari I., Cicero A.F. Effects of nateglinide and glibenclamide on prothrombotic factors in naive type 2 diabetic patients treated with metformin: a 1-year, double-blind, randomized clinical trial. Intern Med 2007, 46(22):1837-1846.
89. Haydardedeoglu B., Simsek E., Kilicdag E.B., Bagis T. Metabolic and endocrine effects of metformin and metformin plus cyclic medroxyprogesterone acetate in women with polycystic ovary syndrome. Int J Gynaecol Obstet 2009 April, 105(1):32-35.
90. Kilicdag E.B., Bagis T., Zeyneloglu H.B., Tarim E., Aslan E., Haydardedeoglu B., Erkanli S. Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone: a randomized study. Hum Reprod 2005 April, 20(4):894-899.
91. Sahin Y., Unluhizarci K., Yilmazsoy A., Yikilmaz A., Aygen E., Kelestimur F. The effects of metformin on metabolic and cardiovascular risk factors in nonobese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2007 December, 67(6):904-908.
92. Sahin M., Tutuncu N.B., Ertugrul D., Tanaci N., Guvener N.D. Effects of metformin or rosiglitazone on serum concentrations of homocysteine, folate, and vitamin B12 in patients with type 2 diabetes mellitus. J Diabetes Complications 2007 March, 21(2):118-123.
93. Sarafidis P.A., Lasaridis A.N., Nilsson P.M., Mouslech T.F., Hitoglou-Makedou A.D., Stafylas P.C., Kazakos K.A., Yovos J.G., Tourkantonis A.A. The effect of rosiglitazone on novel atherosclerotic risk factors in patients with type 2 diabetes mellitus and hypertension. An open-label observational study. Metabolism 2005 September, 54(9):1236-1242.
94. Schachter M., Raziel A., Strassburger D., Rotem C., Ron-El R., Friedler S. Prospective, randomized trial of metformin and vitamins for the reduction of plasma homocysteine in insulin-resistant polycystic ovary syndrome. Fertil Steril 2007 July, 88(1):227-230.
95. Stulc T., Kasalova Z., Krejci H., Dolezalova R., Ceska R. Effect of rosiglitazone on homocysteine and creatinine levels in patients with type 2 diabetes. Atherosclerosis 2005 December, 183(2):367-368.
96. Vrbikova J., Bicikova M., Tallova J., Hill M., Starka L. Homocysteine and steroids levels in metformin treated women with polycystic ovary syndrome. Exp Clin Endocrinol Diabetes 2002 April, 110(2):74-76.
97. Wulffele M.G., Kooy A., Lehert P., Bets D., Ogterop J.C., Borger vdB, Donker A.J., Stehouwer C.D. Effects of short-term treatment with metformin on serum concentrations of homocysteine, folate and vitamin B12 in type 2 diabetes mellitus: a randomized, placebo-controlled trial. J Intern Med 2003 November, 254(5):455-463.
98. Yilmaz M., Bukan N., Ayvaz G., Karakoc A., Toruner F., Cakir N., Arslan M. The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome. Hum Reprod 2005 December, 20(12):3333-3340.
99. Dierkes J., Luley C., Westphal S. Effect of lipid-lowering and anti-hypertensive drugs on plasma homocysteine levels. Vasc Health Risk Manag 2007, 3(1):99-108.
100. Basu T.K., Mann S. Vitamin B-6 normalizes the altered sulfur amino acid status of rats fed diets containing pharmacological levels of niacin without reducing niacin's hypolipidemic effects. J Nutr 1997 January, 127(1):117-121.
101. Wocial B., Berent H., Kostrubiec M., Kuczynska K., Kuch-Wocial A., Nieweglowska N., Homocysteine Adrenergic activity and left ventricular mass in patients with essential hypertension. Blood Press 2002, 11(4):201-205.
102. Do K.Q., Benz B., Sorg O., Pellerin L., Magistretti P.J. beta-Adrenergic stimulation promotes homocysteic acid release from astrocyte cultures: evidence for a role of astrocytes in the modulation of synaptic transmission. J Neurochem 1997 June, 68(6):2386-2394.
103. Sharabi Y., Doolman R., Rosenthal T., Grossman E., Rachima-Maoz C., Nussinovitch N., Sela B. Homocysteine levels in hypertensive patients with a history of cardiac or cerebral atherothrombotic events. Am J Hypertens 1999 August, 12(8 Pt 1):766-771.
104. De Pergola G., Pannacciulli N., Zamboni M., Minenna A., Brocco G., Sciaraffia M., Bosello, Giorgino R. Homocysteine plasma levels are independently associated with insulin resistance in normal weight, overweight and obese pre-menopausal women. Diabetes Nutr Metab 2001 October, 14(5):253-258.
105. Fogari R., Preti P., Zoppi A., Lazzari P., Corradi L., Fogari E., Ciccarelli L., Derosa G. Effects of amlodipine-atorvastatin combination on inflammation markers and insulin sensitivity in normocholesterolemic obese hypertensive patients. Eur J Clin Pharmacol 2006 October, 62(10):817-822.
106. Foley R.N., Wang C., Collins A.J. Cardiovascular risk factor profiles and kidney function stage in the US general population: the NHANES III study. Mayo Clin Proc 2005 October, 80(10):1270-1277.
107. Bauman W.A., Shaw S., Jayatilleke E., Spungen A.M., Herbert V. Increased intake of calcium reverses vitamin B12 malabsorption induced by metformin. Diabetes Care 2000 September, 23(9):1227-1231.
108. Ntaios G., Savopoulos C., Grekas D., Hatzitolios A. The controversial role of B-vitamins in cardiovascular risk: An update. Arch Cardiovasc Dis 2009 December, 102(12):847-854.
109. Sledzinski T., Goyke E., Smolenski R.T., Sledzinski Z., Swierczynski J. Decrease in serum protein carbonyl groups concentration and maintained hyperhomocysteinemia in patients undergoing bariatric surgery. Obes Surg 2009 March, 19(3):321-326.
110. Ferrannini E. Metabolic syndrome: a solution in search of a problem. J Clin Endocrinol Metab 2007 February, 92(2):396-398.
111. Athyros V.G., Bouloukos V.I., Pehlivanidis A.N., Papageorgiou A.A., Dionysopoulou S.G., Symeonidis A.N., Petridis D.I., Kapousouzi M.I., Satsoglou E.A., Mikhailidis D.P. The prevalence of the metabolic syndrome in Greece: the MetS-Greece Multicentre Study. Diabetes Obes Metab 2005 July, 7(4):397-405.
112. Athyros V.G., Karagiannis A., Hatzitolios A.I., Paletas K., Savopoulos C., Giannoglou G., Mikhailidis D.P. Standardized arrangement for a guideline-driven treatment of the metabolic syndrome: the SAGE-METS study. Curr Med Res Opin 2009 April, 25(4):971-980.
113. Athyros V.G., Mikhailidis D.P., Papageorgiou A.A., Didangelos T.P., Ganotakis E.S., Symeonidis A.N., Daskalopoulou S.S., Kakafika A.I., Elisaf M. Prevalence of atherosclerotic vascular disease among subjects with the metabolic syndrome with or without diabetes mellitus: the METS-GREECE Multicentre Study. Curr Med Res Opin 2004 November, 20(11):1691-1701.
114. Ntaios G.C., Savopoulos C.G., Chatzinikolaou A.C., Kaiafa G.D., Hatzitolios A. Vitamins and stroke: the homocysteine hypothesis still in doubt. Neurologist 2008 January, 14(1):2-4.
115. Athyros V.G., Tziomalos K., Mikhailidis D.P., Pagourelias E.D., Kakafika A.I., Skaperdas A., Hatzitolios A., Karagiannis A. Do we need a statin-nicotinic acid-aspirin mini-polypill to treat combined hyperlipidaemia?. Expert Opin Pharmacother 2007 October, 8(14):2267-2277.
116. Athyros V.G., Mikhailidis D.P., Kakafika A.I., Karagiannis A., Hatzitolios A., Tziomalos K., Ganotakis E.S., Liberopoulos E.N., Elisaf M. Identifying and attaining LDL-C goals: mission accomplished? Next target: new therapeutic options to raise HDL-C levels. Curr Drug Targets 2007 March, 8(3):483-488.
117. Felts A.S. Molecule of the Month. TREDAPTIVE (nicotinic acid/laropiprant): a new lipid-modifying therapy for the treatment of LDL-C, HDL-C and triglycerides. Curr Top Med Chem 2008, 8(14):1310.
118. Daskalopoulou S.S., Athyros V.G., Kolovou G.D., Anagnostopoulou K.K., Mikhailidis D.P. Definitions of metabolic syndrome: Where are we now?. Curr Vasc Pharmacol 2006, 4:185-197.
119. Athyros V.G., Ganotakis E.S., Elisaf M., Mikhailidis D.P. The prevalence of the metabolic syndrome using the National Cholesterol Educational Program and International Diabetes Federation definitions. Curr Med Res Opin 2005, 21:1157-1159.